A Study for Expanding Application Sites for Rotigotine Transdermal Patch

Overview

Journal Parkinsons Dis

Publisher Wiley

Date 2020 Aug 28

PMID 32850112

Citations 1

Authors

Hitoshi Kujirai

Sakiko Itaya

Yumi Ono

Makoto Takahashi

Akira Inaba

Yasushi Shimo

Nobutaka Hattori

Satoshi Orimo

Affiliations

Soon will be listed here.

Abstract

The rotigotine transdermal patch (RTP) is a dopamine agonist used to treat Parkinson's disease (PD). Some PD patients cannot continue RTP treatment due to application site reactions. We explored sites for RTP where application site reactions are less severe than those in the six approved application sites. Thirty PD patients (12 men, mean age = 76 years) who underwent RTP at the approved sites and had some application site reactions were enrolled in this study. When applying the RTP to the approved application sites for more than four weeks (pre-RTP) and then on the shin for the following four weeks (post-RTP), skin reactions, itching evaluated using the skin irritation score, motor symptoms, clinical global impressions scale, and plasma rotigotine concentration were examined. The mean visual analogue scale and skin irritation score in the post-RTP group were significantly lower than those in the pre-RTP group. The mean Movement Disorder Society-Unified Parkinson's Disease Rating Scale part III score in the post-RTP group was slightly but significantly lower than that in the pre-RTP group. Plasma rotigotine concentration in the post-RTP group was slightly but significantly lower than that in the pre-RTP group. These results indicate that the shin can be a useful application site for RTP.

Citing Articles

Translation from Preclinical Research to Clinical Trials: Transdermal Drug Delivery for Neurodegenerative and Mental Disorders.

Nguyen-Thi P, Vo T, Le H, Nguyen N, Nguyen T, Van Vo G Pharm Res. 2024; 41(6):1045-1092.

PMID: 38862719 DOI: 10.1007/s11095-024-03718-x.

References

Woitalla D, Kassubek J, Timmermann L, Lauterbach T, Berkels R, Grieger F . Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial. Parkinsonism Relat Disord. 2015; 21(3):199-204. DOI: 10.1016/j.parkreldis.2014.11.024. View

Tomlinson C, Stowe R, Patel S, Rick C, Gray R, Clarke C . Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010; 25(15):2649-53. DOI: 10.1002/mds.23429. View

Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K . Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011; 26(1):90-9. PMC: 3072524. DOI: 10.1002/mds.23441. View

Nicholas A, Borgohain R, Chana P, Surmann E, Thompson E, Bauer L . A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease. J Parkinsons Dis. 2014; 4(3):361-73. DOI: 10.3233/JPD-130320. View

. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol. 2003; 60(12):1721-8. DOI: 10.1001/archneur.60.12.1721. View

Mohamed S, Riva R, Contin M . Novel UHPLC-MS/MS method for the determination of rotigotine in the plasma of patients with Parkinson's disease. Biomed Chromatogr. 2017; 31(9). DOI: 10.1002/bmc.3944. View

Postuma R, Berg D, Stern M, Poewe W, Olanow C, Oertel W . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015; 30(12):1591-601. DOI: 10.1002/mds.26424. View

Busner J, Targum S . The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2010; 4(7):28-37. PMC: 2880930. View

de la Fuente-Fernandez R, Ruth T, Sossi V, Schulzer M, Calne D, Stoessl A . Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science. 2001; 293(5532):1164-6. DOI: 10.1126/science.1060937. View

10.

Otberg N, Richter H, Schaefer H, Blume-Peytavi U, Sterry W, Lademann J . Variations of hair follicle size and distribution in different body sites. J Invest Dermatol. 2004; 122(1):14-9. DOI: 10.1046/j.0022-202X.2003.22110.x. View

11.

Jankovic J, Watts R, Martin W, Boroojerdi B . Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007; 64(5):676-82. DOI: 10.1001/archneur.64.5.676. View

12.

Johnson E . Visual analog scale (VAS). Am J Phys Med Rehabil. 2001; 80(10):717. DOI: 10.1097/00002060-200110000-00001. View

13.

Mizuno Y, Nomoto M, Hasegawa K, Hattori N, Kondo T, Murata M . Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study. Parkinsonism Relat Disord. 2014; 20(12):1388-93. DOI: 10.1016/j.parkreldis.2014.10.005. View

14.

Garcia-Ruiz P, Castrillo J, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P . Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014; 85(8):840-4. DOI: 10.1136/jnnp-2013-306787. View

15.

Brusa L, Pavino V, Massimetti M, Bove R, Iani C, Stanzione P . The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients. Funct Neurol. 2013; 28(1):13-7. PMC: 3812723. View

16.

Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B . A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. 2016; 23(8):1255-61. DOI: 10.1111/ene.13034. View

17.

Giladi N, Fichtner A, Poewe W, Boroojerdi B . Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease. J Neural Transm (Vienna). 2010; 117(12):1395-9. DOI: 10.1007/s00702-010-0506-4. View

18.

Podsiadlo D, Richardson S . The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991; 39(2):142-8. DOI: 10.1111/j.1532-5415.1991.tb01616.x. View

19.

Elshoff J, Braun M, Andreas J, Middle M, Cawello W . Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther. 2012; 34(4):966-78. DOI: 10.1016/j.clinthera.2012.02.008. View

20.

Scheller D, Ullmer C, Berkels R, Gwarek M, Lubbert H . The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol. 2008; 379(1):73-86. DOI: 10.1007/s00210-008-0341-4. View